CorMedix 경영진
경영진 기준 점검 2/4
CorMedix CEO는 Joe Todisco, May2022 에 임명되었습니다 의 임기는 4.17 년입니다. 총 연간 보상은 $6.10M, 11.2% 급여 및 88.8% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $3.14M 가치에 해당하는 회사 주식의 0.51% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.3 년과 4.2 년입니다.
핵심 정보
Joe Todisco
최고경영자
US$6.1m
총 보수
| CEO 급여 비율 | 11.22% |
| CEO 재임 기간 | 4yrs |
| CEO 지분 보유율 | 0.5% |
| 경영진 평균 재임 기간 | 2.3yrs |
| 이사회 평균 재임 기간 | 4.2yrs |
최근 경영진 업데이트
Recent updates
Seeking Alpha • May 18
CorMedix: Long-Term Prospects Remain Poor Despite Q1 Beat
Summary CorMedix remains a Sell as Q1 outperformance is unsustainable due to non-recurring revenue adjustments and looming reimbursement headwinds for DefenCath. DefenCath faces an 80% sequential revenue decline post-TDAPA, with management reaffirming 2027 guidance and signaling no near-term rebound. Free cash flow margins peaked in Q1 but are projected to normalize below 10% as product mix shifts and operating expenses rise. Delays in the TPN trial and lackluster Rezzayo data diminish pipeline optionality, reinforcing a cautious long-term outlook. Read the full article on Seeking Alpha
내러티브 업데이트 • May 14
CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events
CRMD has resolved its primary binary risk (ReSPECT positive), delivered a Q1 revenue beat 21% above consensus with guidance raised, and now trades at 5.1x trough-year EV/EBITDA — pricing that reflects little credit for a confirmed FDA filing pathway for a >$1B TAM asset, a recovering DefenCath post-TDAPA trajectory, or $178M in cash growing each quarter, with a bear case floor of today's price and base case upside of +45%. Investment Thesis: The ReSPECT positive read and sNDA timeline to 2H 2026 de-risk the REZZAYO prophylaxis asset from speculative to near-commercial, with orphan drug exclusivity through 2035 and patents through 2038 providing durable protection on a >$1B addressable market Q1 2026 DefenCath volume trajectory ("higher utilization by outpatient dialysis customers") demonstrates that underlying clinical demand is intact independent of TDAPA pricing mechanics — the TDAPA step-down is a revenue timing event, not a demand destruction event The guidance raise to $325–345M revenue and $115–135M adj EBITDA in what management describes as a "trough" year, combined with $178M cash and ongoing buybacks, gives the company financial flexibility to execute the sNDA and fund TPN enrollment without any capital raise The Melinta acquisition structure ($30M goodwill, $63.9M buyback authorization remaining, competent management team retained) continues to demonstrate capital discipline, and the commercial platform synergies are beginning to show in the normalized opex trajectory Multiple near-term catalysts — Q2 2026 earnings (last strong DefenCath quarter before step-down), sNDA submission date announcement, Medicare Advantage contracting updates — provide re-rating opportunities before year-end Risk Considerations: FDA could request additional data or issue a CRL on the REZZAYO prophylaxis sNDA given the narrow 1.7 percentage point non-inferiority margin — the regulatory path is constructive but not guaranteed, and a setback here remains the largest remaining value driver at risk The TDAPA step-down begins July 1 and will drive a sharp sequential revenue decline from Q2 to Q3/Q4 2026; if DefenCath volume falls more than expected when pricing compresses (i.e., dialysis chains reduce utilization to manage costs), the 2027 recovery thesis weakens materially TPN program delay to 2028 completion extends the timeline to $500–750M TAM access by 18+ months and introduces ongoing enrollment execution risk, particularly for a study requiring 12 months of follow-up per patient at home Securities class action litigation in active discovery (completion September 2026) with an unsuccessful prior mediation represents an unquantified cash liability and management distraction at a strategically critical juncture; a trial or unfavorable settlement could be disruptive Pharmaceutical tariff exposure from the April 2 executive order on API imports creates margin uncertainty that the company cannot yet quantify, with European CMO dependence for both DefenCath and the Melinta portfolio unlikely to be fully onshored within 12 months
내러티브 업데이트 • May 11
CRMD: Mixed Research And Phase III Success Will Support Undervalued Shares
CorMedix's analyst price target has changed to $15.00 from $14.57 as analysts update their models for revenue growth, profit margins, discount rate and future P/E assumptions following mixed recent Street research. Analyst Commentary Recent research on CorMedix reflects a mix of optimism and caution as analysts adjust their valuation frameworks and expectations for execution.내러티브 업데이트 • Apr 30
CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events
With ReSPECT Phase III positive this week, CRMD has resolved its single largest binary risk and now trades at a 63% discount to base case intrinsic value with a bear case floor only 8% below current price, as the REZZAYO prophylaxis sNDA path, DefenCath TPN pipeline, and post-TDAPA revenue recovery converge toward a 2027 inflection that the $7 stock price is not remotely reflecting.내러티브 업데이트 • Apr 23
CRMD: Reaffirmed 2026 Outlook And Buyback Plan Will Support Undervalued Shares
Analysts have trimmed their 12 month price target on CorMedix to $13 from $15, reflecting updated views on revenue growth, profitability, and appropriate future P/E levels for the stock. Analyst Commentary Recent price target revisions to US$13 from US$15 sit alongside continued positive ratings, which gives a mixed message for investors.내러티브 업데이트 • Apr 06
CRMD: Investor Day Will Reframe Lower Guidance And Support Undervalued Outlook
Narrative Update on CorMedix Analysts have reduced their blended price targets on CorMedix by several dollars to a range of roughly $13 to $16, citing updated company revenue guidance that is materially below prior Street expectations, especially for DefenCath in 2026 and 2027. Analyst Commentary Street research on CorMedix has shifted toward lower valuation targets after the company issued revenue guidance for 2026 and 2027 that sits well below prior expectations, particularly for DefenCath.새로운 내러티브 • Apr 02
CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events
Investment Thesis DefenCath's regulatory moat (only FDA-approved antimicrobial CLS in the U.S., NCE+GAIN exclusivity through 2033, composition patent to 2042) is intact and the 72% real-world CRBSI reduction is standard-of-care quality data; the TDAPA pricing step-down is a commercial mechanics event, not a competitive displacement event The stock at $7.02 prices in approximately the bear case ($6.54), meaning investors are effectively receiving the REZZAYO prophylaxis Phase III binary and the DefenCath TPN pipeline for free — an unusual asymmetry for a cash-flow-positive commercial pharma company Operating cash flow of $175M in FY2025 and $148.5M in cash provides full self-funding of pipeline without dilution risk, and the $75M buyback at current prices represents management's explicit capital allocation conviction about intrinsic value The Melinta acquisition was well-priced ($30M goodwill on $391M identified intangibles) and adds an annualizing $130M+ revenue stream with shared call points that provide SG&A leverage as the combined platform scales Post-TDAPA recovery in 2027 (3x–5x higher add-on payment vs. H2 2026 per management, plus Medicare Advantage contracting upside not in guidance) provides a clearly identified catalyst path back to re-rating independent of pipeline success Risk Considerations ReSPECT Phase III failure (data Q2 2026) would eliminate ~$221M of base case rNPV, trigger impairment of the $143M IPR&D intangible, and likely reset the stock to the $5.60 52-week low or below — this is the primary binary risk and is near-term Customer concentration at 79% revenue from three accounts is structurally dangerous; any publicly announced reduction in DefenCath orders from a major dialysis organization would be a material negative event with little warning The Q4 GAAP EPS miss ($0.16 vs.내러티브 업데이트 • Mar 22
CRMD: Investor Day Will Clarify Lower Guidance And Highlight Perceived Upside
Analysts have trimmed CorMedix price targets by $2 to $9, with recent cuts such as $20 to $16 and $15 to $13, reflecting updated views on DefenCath revenue guidance and the company outlook shared in recent research notes. Analyst Commentary Recent research reflects a reset in expectations for CorMedix as analysts align their models with the latest DefenCath revenue guidance and management commentary.내러티브 업데이트 • Mar 08
CRMD: Investor Day Reset On Lower Guidance Will Highlight Undervalued Upside
Narrative Update on CorMedix The analyst price target for CorMedix has been trimmed from about $14.86 to roughly $14.57. Analysts are recalibrating their models in light of lower revenue growth and margin expectations, along with a more conservative view on long term DefenCath contribution, as reflected in recent target cuts from $20 to $16, $15 to $13, and other reductions across the Street.내러티브 업데이트 • Feb 21
CRMD: Investor Day Will Reframe Lower Guidance And Support Undervalued Thesis
Analysts have trimmed their average price targets on CorMedix by a mid single digit dollar amount, citing the company's new FY26 and 2027 DefenCath revenue guidance, which sits well below prior Street expectations, as a key driver of their revised views. Analyst Commentary Bullish Takeaways Bullish analysts still see room for upside even with price targets trimmed, suggesting they view the lower guidance as already influencing valuation assumptions.내러티브 업데이트 • Feb 07
CRMD: Investor Day And New Revenue Guidance Will Shape Bullish Case
Analysts have trimmed their price targets on CorMedix, with our fair value estimate moving from US$16.86 to US$14.86 as they factor in lower revenue growth and profit margin assumptions, despite a higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts still see upside potential in CorMedix shares, pointing to the higher future P/E multiple being used in their models as a sign that they are willing to ascribe a premium to the company despite reduced revenue assumptions.분석 기사 • Feb 06
CorMedix Inc. (NASDAQ:CRMD) Not Doing Enough For Some Investors As Its Shares Slump 35%
The CorMedix Inc. ( NASDAQ:CRMD ) share price has fared very poorly over the last month, falling by a substantial 35...내러티브 업데이트 • Jan 22
CRMD: Updated Revenue Guidance And Investor Day Will Shape Upside Potential
Narrative Update Analysts have trimmed their average price target for CorMedix from about US$19 to roughly US$16.86. This reflects updated expectations for slower revenue growth and lower profit margins, partially offset by a higher assumed future P/E multiple following the company's reduced long term guidance and recent research updates.내러티브 업데이트 • Jan 07
CRMD: Robust Q3 Sales And Synergy Progress Will Support Further Upside
Narrative Update: CorMedix Analysts have maintained their fair value estimate for CorMedix at $19.00. Recent Street research highlights a $14.00 price target supported by what they describe as "robust" preliminary Q3 sales, better visibility into near term operating synergies, and the recent stock pullback.분석 기사 • Dec 23
CorMedix Inc.'s (NASDAQ:CRMD) 28% Jump Shows Its Popularity With Investors
CorMedix Inc. ( NASDAQ:CRMD ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...내러티브 업데이트 • Dec 14
CRMD: Robust Q3 Sales Will Support Stronger Upside Momentum Ahead
Analysts have modestly raised their price target on CorMedix to $19.00 from $14.00, citing robust preliminary Q3 sales, clearer visibility into near term operating synergies, and the recent stock pullback as key drivers of their more constructive outlook. Analyst Commentary Bullish Takeaways Bullish analysts highlight that robust preliminary Q3 sales provide early validation of CorMedix's commercial strategy and support the raised price target.내러티브 업데이트 • Nov 28
CRMD: Q3 Sales Strength And New Buy Rating Will Drive Momentum Forward
Analysts have raised their price target for CorMedix to $14 from the previous level, citing stronger than expected Q3 sales and improved visibility into operational performance as key drivers of the updated outlook. Analyst Commentary Following the recent preliminary Q3 results, analysts have provided updated insights into CorMedix’s outlook, highlighting both encouraging signs and ongoing areas of caution for the company’s future performance.내러티브 업데이트 • Nov 14
CRMD: Strong Q3 Sales Will Drive Renewed Uptrend Momentum
Analysts have lowered their price target for CorMedix from $20.40 to $19.00, citing a more moderate revenue growth outlook and adjusted profit expectations. This comes despite optimism about robust Q3 sales and operational improvements.내러티브 업데이트 • Sep 04
Acquisition And Pipeline Expansion Will Unlock Healthcare Potential
CorMedix’s consensus price target has edged up to $20.40, as analysts see greater revenue potential from DefenCath’s accelerating launch, expanded patient uptake, and supportive reimbursement dynamics, offsetting equity-related dilution concerns. Analyst Commentary The recent $85M equity offering extends CorMedix's cash runway but introduces dilution, prompting a reduced price target from previous levels based on valuation concerns.분석 기사 • Aug 14
Statutory Earnings May Not Be The Best Way To Understand CorMedix's (NASDAQ:CRMD) True Position
The latest earnings release from CorMedix Inc. ( NASDAQ:CRMD ) disappointed investors. Our analysis found several...분석 기사 • Aug 09
It's A Story Of Risk Vs Reward With CorMedix Inc. (NASDAQ:CRMD)
NasdaqGM:CRMD 1 Year Share Price vs Fair Value Explore CorMedix's Fair Values from the Community and select yours With...분석 기사 • Jun 27
Bullish: Analysts Just Made A Meaningful Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts
Celebrations may be in order for CorMedix Inc. ( NASDAQ:CRMD ) shareholders, with the analysts delivering a significant...
새로운 내러티브 • Apr 30
DefenCath Launch Will Boost Inpatient And Dialysis Opportunities
Strong revenue growth prospects from DefenCath's successful launch and expansion into new segments like inpatient facilities and partnerships.Seeking Alpha • Mar 26
The Hidden Risks Behind CorMedix's First Profitable Quarter
Summary CorMedix Inc.'s DefenCath reduces catheter infections by 71%, but the limited market potential challenges long-term adoption. Early strong revenues likely reflect inventory building rather than sustained utilization patterns. Special reimbursements boosting current profits will expire, threatening future margins and pricing power. Half-year guidance signals limited visibility, with management warning of inventory adjustments and price erosion. Monte Carlo simulations suggest CRMD faces more downside risk (25%) than upside potential (8.8%). Read the full article on Seeking Alpha분석 기사 • Jan 17
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. Indeed, CorMedix...Seeking Alpha • Jan 07
CorMedix: Finally In Commercialization Mode
Summary CorMedix Inc.'s DefenCath, an antimicrobial catheter lock solution, shows considerable promise in reducing catheter-related bloodstream infections. The product was approved earlier this year and has seen solid initial sales traction. Analyst firms are optimistic about the company's prospects, even as the stock is down just over a third from recent highs. An analysis of CorMedix follows in the paragraphs below. Read the full article on Seeking Alpha분석 기사 • Dec 13
CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark
When you see that almost half of the companies in the Pharmaceuticals industry in the United States have price-to-sales...분석 기사 • Nov 14
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns
Key Insights CorMedix to hold its Annual General Meeting on 21st of November CEO Joe Todisco's total compensation...분석 기사 • Nov 04
Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts
Celebrations may be in order for CorMedix Inc. ( NASDAQ:CRMD ) shareholders, with the analysts delivering a significant...Seeking Alpha • Oct 28
CorMedix 2.0: New Leadership, New Approval, New Focus
Summary CorMedix is a biopharmaceutical company that has undergone a re-birth as it enters a new phase with FDA approval of its anti-infective catheter solution, DefenCath. The company has faced challenges in the past, including management issues and regulatory delays, but now warrants a fresh look and valuation as the company executes on commercialization. DefenCath offers a unique solution for preventing catheter-related bloodstream infections, with the potential to reduce costs and save lives. Read the full article on Seeking AlphaSeeking Alpha • Oct 19
CorMedix: Delayed Approval, Low Cash, Good Prospects
Summary CorMedix's DefenCath, an FDA-approved antimicrobial catheter lock solution, significantly reduces catheter-related bloodstream infections, addressing a critical need in hemodialysis patients. DefenCath's market exclusivity and reimbursement strategies position it well in the growing $2.6bn CRBSI market, with significant potential for revenue. Despite past challenges, CorMedix's financial outlook is improving, but additional funds are needed for future trials in new indications. Investors should await Q3 earnings data for a clearer picture, as current stock spikes are driven by DefenCath's recent launch. Read the full article on Seeking Alpha분석 기사 • Sep 30
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, CorMedix...분석 기사 • Apr 06
We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Nov 02
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Jul 31
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$180m |
| Dec 31 2025 | US$6m | US$684k | US$162m |
| Sep 30 2025 | n/a | n/a | US$162m |
| Jun 30 2025 | n/a | n/a | US$51m |
| Mar 31 2025 | n/a | n/a | US$17m |
| Dec 31 2024 | US$2m | US$639k | -US$18m |
| Sep 30 2024 | n/a | n/a | -US$46m |
| Jun 30 2024 | n/a | n/a | -US$53m |
| Mar 31 2024 | n/a | n/a | -US$50m |
| Dec 31 2023 | US$2m | US$617k | -US$46m |
| Sep 30 2023 | n/a | n/a | -US$40m |
| Jun 30 2023 | n/a | n/a | -US$37m |
| Mar 31 2023 | n/a | n/a | -US$33m |
| Dec 31 2022 | US$3m | US$378k | -US$30m |
보상 대 시장: Joe의 총 보수(USD6.10M)는 US 시장에서 비슷한 규모 기업의 평균(USD3.79M)보다 높습니다.
보상과 수익: Joe의 보상은 지난 1년 동안 20% 이상 증가했습니다.
CEO
Joe Todisco (49 yo)
4yrs
재임 기간
US$6,101,176
보수
Mr. Joseph Todisco, also known as Joe, MBA, is Director of Airway Therapeutics, Inc. from April 13, 2026. Mr. Todisco serves as Chief Executive Officer of CorMedix Inc. since May 10, 2022 and is its Chairm...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Chairman of the Board of Directors | 4yrs | US$6.10m | 0.51% $ 3.1m | |
| Executive VP | 2.3yrs | US$3.74m | 0.082% $ 502.5k | |
| EVP, Chief Legal and Compliance Officer & Corporate Secretary | 2.4yrs | US$3.77m | 0.057% $ 351.7k | |
| EVP & Chief Financial Officer | less than a year | 데이터 없음 | 0.011% $ 66.0k | |
| SVP & Chief Human Resource Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| EVP & Chief Business Officer | less than a year | US$1.09m | 0.035% $ 211.7k | |
| Senior VP & Head of Global Quality | 4yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Head of Technical Operations | 3.3yrs | 데이터 없음 | 데이터 없음 | |
| EVP & Chief Commercial Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Market Access | no data | 데이터 없음 | 데이터 없음 | |
| Executive Director of Clinical Portfolio Management | no data | 데이터 없음 | 데이터 없음 |
2.3yrs
평균 재임 기간
50.5yo
평균 나이
경험이 풍부한 관리: CRMD의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.3 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Chairman of the Board of Directors | 4.2yrs | US$6.10m | 0.51% $ 3.1m | |
| Lead Independent Director | 10.1yrs | US$433.25k | 0.29% $ 1.8m | |
| Independent Director | 7.2yrs | US$379.25k | 0.051% $ 314.8k | |
| Independent Director | 10.8yrs | US$387.25k | 0.049% $ 300.9k | |
| Independent Director | 8.9yrs | US$397.25k | 0.12% $ 762.5k | |
| Independent Director | 5.5yrs | US$379.25k | 0.049% $ 299.8k | |
| Member of Scientific Advisor Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 4.1yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 4.1yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 4.1yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 4.1yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 4.1yrs | 데이터 없음 | 데이터 없음 |
4.2yrs
평균 재임 기간
69yo
평균 나이
경험이 풍부한 이사회: CRMD의 이사회는 경험이 있음으로 간주됩니다(평균 재임 4.2 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/20 05:12 |
| 종가 | 2026/05/20 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
CorMedix Inc.는 18명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Jason Butler | Citizens JMP Securities, LLC |
| Jason Kolbert | D. Boral Capital LLC. |